- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00596817
Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes
February 13, 2014 updated by: H. Lundbeck A/S
A Double-blind, Randomised, Placebo-controlled, Multicentre, Relapse-prevention Study With Two Doses of [Vortioxetine] Lu AA21004 in Patients With Major Depressive Disorder
This study will evaluate the efficacy of Vortioxetine in the prevention of relapse of major depressive episodes in patients who responded to open-label treatment with Vortioxetine.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
639
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Major Depressive Episode (MDE) as the primary diagnosis according to DSM-IV TR criteria
- At least one other MDE before the current one
- Moderate to severe depression
Exclusion Criteria:
- Any current psychiatric disorder other than Major Depressive Disorder (MDD) as defined in the DSM-IV TR
- Any substance disorder within the previous 6 months
- Female patients of childbearing potential who are not using effective contraception
- Use of any psychoactive medication 2 weeks prior to screening and during the study
Randomisation Criteria: Patients in remission (MADRS total score <=10) at both Week 10 and Week 12
Other protocol-defined inclusion and exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
capsules, daily, orally
|
|
Experimental: Vortioxetine: 5 or 10 mg
|
encapsulated tablets, daily, orally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Relapse Within First 24 Weeks of the Double-blind Period Based on a MADRS Total Score >=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator
Time Frame: Within first 24 weeks of the double-blind period
|
The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom).
The 10 items represent the core symptoms of depressive illness.
The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days.
Total score from 0 to 60.
The higher the score, the more severe.
|
Within first 24 weeks of the double-blind period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Relapse During the Entire Double-blind Period Based on a MADRS Total Score >=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator
Time Frame: Within 64 weeks of the double-blind period
|
Within 64 weeks of the double-blind period
|
|
|
Change From Double-blind Baseline in MADRS Total Score After 24 Weeks of Double-blind Treatment
Time Frame: Double-blind Baseline and Week 24 of the double-blind period
|
Double-blind Baseline and Week 24 of the double-blind period
|
|
|
Change From Double-blind Baseline in HAM-D-17 Total Score After 24 Weeks of Double-blind Treatment
Time Frame: Double-blind Baseline and Week 24 of the double-blind period
|
The Hamilton Depression Scale - 17 items (HAM-D-17) measures depression severity.
Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 52.
The higher the score, the more severe.
|
Double-blind Baseline and Week 24 of the double-blind period
|
|
Change From Double-blind Baseline in HAM-A Total Score After 24 Weeks of Double-blind Treatment
Time Frame: Double-blind Baseline and Week 24 of the double-blind period
|
The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms.
Each symptom is rated from 0 (absent) to 4 (maximum severity).
Total score from 0 to 56.
The higher the score, the more severe.
|
Double-blind Baseline and Week 24 of the double-blind period
|
|
Change From Double-blind Baseline in CGI-S Score After 24 Weeks of Double-blind Treatment
Time Frame: Double-blind Baseline and Week 24 of the double-blind period
|
The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.
|
Double-blind Baseline and Week 24 of the double-blind period
|
|
Proportion of Responders at Week 24 of the Double-blind Period (Response Defined as a >=50% Reduction in MADRS Total Score From Open-label Baseline)
Time Frame: Week 24 of the double-blind period (Counted From Open-label Baseline)
|
Week 24 of the double-blind period (Counted From Open-label Baseline)
|
|
|
Proportion of Remitters at Week 24 of the Double-blind Period (Remission Defined as a MADRS Total Score <=10)
Time Frame: Week 24 of the double-blind period
|
Week 24 of the double-blind period
|
|
|
Change From Double-blind Baseline in SDS Total Score at Week 24 of the Double-blind Period
Time Frame: Week 24 of the double-blind period (Counted From Double-blind Baseline)
|
The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment.
The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment.
The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired).
The higher the score, the more severe.
|
Week 24 of the double-blind period (Counted From Double-blind Baseline)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- McIntyre RS, Florea I, Tonnoir B, Loft H, Lam RW, Christensen MC. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder. J Clin Psychiatry. 2017 Jan;78(1):115-121. doi: 10.4088/JCP.16m10744.
- Christensen MC, Florea I, Loft H, McIntyre RS. Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma. J Affect Disord. 2020 Feb 15;263:258-266. doi: 10.1016/j.jad.2019.11.074. Epub 2019 Nov 13.
- Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012 Nov;26(11):1408-16. doi: 10.1177/0269881112441866. Epub 2012 Apr 9.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2007
Primary Completion (Actual)
September 1, 2009
Study Completion (Actual)
October 1, 2009
Study Registration Dates
First Submitted
January 8, 2008
First Submitted That Met QC Criteria
January 8, 2008
First Posted (Estimate)
January 17, 2008
Study Record Updates
Last Update Posted (Estimate)
March 31, 2014
Last Update Submitted That Met QC Criteria
February 13, 2014
Last Verified
February 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Pathologic Processes
- Mood Disorders
- Disease Attributes
- Depression
- Depressive Disorder
- Recurrence
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin Antagonists
- Anti-Anxiety Agents
- Serotonin 5-HT3 Receptor Antagonists
- Vortioxetine
Other Study ID Numbers
- 11985A
- 2007-001871-13 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.